Search Technologies

Researchers at the National Cancer Institute (NCI) have developed a technology that provides methods of performing adoptive cell transfer (ACT), an immunotherapeutic approach for cancer treatment, by administering a heterodimeric Interleukin 15/Interleukin 15 receptor alpha (IL-15/IL-15Rα) complex (hetlL-15) in the absence of lymphodepletion, thereby eliminating any lymphodepletion-associated detrimental side effects.

Researchers at the National Cancer Institute found that the absence of CD47 enhances stem cell renewal in vitro and in vivo by increasing expression of four stem cell transcription factors.

Researchers at the National Institute on Aging (NIA) have developed a novel strategy for rendering weakly or non-immunogenic, shared (between self and tumor) antigens immunogenic, or able to produce an immune response. Further, they have created therapeutic polypeptides comprising tumor-associated embryonic antigens and chemoattractant ligands. Cancers targeted by these developments include breast, renal, lung, ovarian, and hematological cancers.

Researchers at the National Cancer Institute (NCI) have developed a combination of immunoadjuvants and immune checkpoint inhibitors to stimulate an immune response against cancer. The combination therapy has been tested in xenograft models and shown successful for both treatment of an existing tumor and resistance to re-challenge. Researchers at the NCI seek licensing and/or co-development research collaborations for this invention.

Researchers at the National Cancer Institute (NCI) have developed an invention describing the binding domain (G2BD) for the ubiquitin-conjugating enzyme Ube2G2 in the gp78 ubiqutin ligase protein. The invention involves modulating the interaction between the gp78 protein and the conjugating enzyme Ube2G2. Interruption of this interaction will block degradation from the endoplasmic reticulum (ER), resulting in ER stress, unfolded protein response, and, ultimately, apoptosis in some cancer cells. The NCI seeks licensing and/or co-development partners for this invention.

The National Cancer Institute's Urologic Oncology Branch is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the use of Tempol to target HIF-2a in cancer.

Researchers at the National Cancer Institute (NCI) have isolated T cell receptors (TCRs) that target specific mutations in the epidermal growth factor receptor (EGFR). The mutated protein recognized by these TCRs is frequently expressed in non-small cell lung cancer (NSCLC). These TCRs can be used for a variety of therapeutic applications, including engineered adoptive cell immunotherapy. Researchers at the NCI seek licensing and/or co-development research collaborations for these novel T cell receptors that recognize EGFR mutations.

The NCI seeks parties interested in research co-development and/or licensing of TCRs targeting the BRAF V600E mutation. These TCRs are HLA-A*0301 restricted. The BRAF V600E mutation is common among cancer patients, giving the TCRs broad therapeutic potential in immunotherapy against multiple cancers.

It is well known that overactive Ras signaling is linked to many forms of cancer, and despite intensive efforts worldwide to develop effective inhibitors of Ras, to date there is no anti-Ras inhibitor in clinical use. Researchers at the NCI’s Cancer and Inflammation Program, in collaboration with scientists at Vanderbilt University and the University of Illinois in Chicago, have identified a number of small peptidomimetic compounds that bind to Ras proteins with nanomolar affinity. NCI’s Cancer and Inflammation Program seeks partners interested in licensing or co-development of synthetic, highly potent cell-permeable inhibitors of Ras that bind to the protein directly.